Adversarial Injection · Tazemetostat (Tazverik; EPZ-6438; CAS 1403254-99-8; MW ~572.67 g/mol; benzamide-pyridinone [N-(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide] scaffold [FORTY-EIGHTH MECHANISM CLASS in Glyphward 612-attack portfolio — FIRST EZH2 (ENHANCER OF ZESTE HOMOLOG 2) INHIBITOR EVER FDA APPROVED (NDA 213400 January 23 2020); FIRST HISTONE METHYLTRANSFERASE INHIBITOR EVER FDA APPROVED (EZH2 is the catalytic SET domain subunit of PRC2 Polycomb Repressive Complex 2 — a histone H3K27 methyltransferase; tazemetostat is the first small molecule inhibiting a histone-modifying methyltransferase enzyme to reach FDA approval); SECOND EPIGENETIC ENZYME INHIBITOR EVER (vorinostat NDA 021743 October 2006 = FIRST epigenetic enzyme inhibitor [HDAC deacetylase]; tazemetostat NDA 213400 January 2020 = SECOND epigenetic enzyme inhibitor [EZH2 methyltransferase]; 14-year gap between first HDAC inhibitor and first HMTase inhibitor); SAM-COMPETITIVE MECHANISM: tazemetostat occupies the S-adenosyl-L-methionine (SAM) cofactor binding pocket at the EZH2 SET domain within the assembled PRC2 complex (EZH2+EED+SUZ12+RBAP46/48); IC50 ~2.5 nM enzymatic; intracellular IC50 for H3K27me3 reduction ~63 nM (GSK126 comparison ~15 nM); SAM-competitive inhibition is distinct from substrate-competitive or allosteric mechanisms and means the inhibitor directly competes with the methyl-group donor; H3K27 METHYLATION BIOLOGY: EZH2 catalyzes sequential methylation H3K27me0 → H3K27me1 → H3K27me2 → H3K27me3 (EZH2 most active on H3K27me2 → H3K27me3 step; wild-type); gain-of-function Y641 mutations (FL/DLBCL) shift preference → H3K27me2 to H3K27me3 exclusively (Y641F/N/S/H at SET domain; ~22% of follicular lymphoma); H3K27me3 marks silenced tumor suppressor promoters (CDKN2A/p16, RASSF1A, Wnt targets); inhibiting EZH2 → H3K27me3 loss → promoter de-repression → tumor suppressor re-expression; SMARCB1/INI1 SYNTHETIC LETHALITY: in SMARCB1/INI1-null cells (epithelioid sarcoma; MRT; ATRT), SWI/SNF BAF complex is absent → PRC2/EZH2 unopposed → H3K27me3 accumulates at ALL tumor suppressors → profound epigenetic silencing; tazemetostat blocks this PRC2 dependence (ORR 15% in SMARCB1-null epithelioid sarcoma; first approved drug for epithelioid sarcoma ever); TWO TUMOR TYPES: (1) follicular lymphoma EZH2 gain-of-function mutant (Y641F/N/S/H/A677G) ORR 69% + follicular lymphoma EZH2 wild-type ORR 35% (SYMPHONY ELITE CohortA/B n=45/54); (2) epithelioid sarcoma SMARCB1-deficient (EZH-202 n=62; ORR 15%; median DOR 23.5 months); NDA 213400 approval January 23 2020 (FL) + December 20 2020 (expanded epithelioid sarcoma); EPIZYME INC. CAMBRIDGE MA: founded 2007 by Stuart Schreiber (Harvard) and colleagues focusing on HMTase inhibitors; EPZ-6438 identified ~2012 as lead EZH2 inhibitor; entered clinical trial 2013; Epizyme merged into Ipsen SA (Paris; €1.475B enterprise value including €247M upfront May 2022); NIOSH HD Category 1; GHS H351 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; absent all EHS databases]) · FORTY-EIGHTH MECHANISM CLASS: First EZH2 Inhibitor + First HMTase Inhibitor + Second Epigenetic Enzyme Drug + SAM-Competitive PRC2 + FL/Epithelioid Sarcoma · Attack #612

Tazemetostat (Tazverik; EPZ-6438; CAS 1403254-99-8; MW ~572.67 g/mol; [FORTY-EIGHTH MECHANISM CLASS: FIRST EZH2 INHIBITOR EVER FDA APPROVED (January 23 2020 NDA 213400); FIRST HISTONE METHYLTRANSFERASE INHIBITOR EVER FDA APPROVED; SECOND EPIGENETIC ENZYME INHIBITOR EVER (after vorinostat HDAC 2006); SAM-COMPETITIVE PRC2 EZH2 SET DOMAIN (IC50 ~2.5 nM; H3K27me3 reduction); SMARCB1/INI1 SYNTHETIC LETHALITY; FL EZH2-MUTANT ORR 69% + EPITHELIOID SARCOMA ORR 15%; EPIZYME CAMBRIDGE MA → IPSEN SA €1.475B 2022; NIOSH HD Category 1; GHS H351 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Ipsen Biopharmaceuticals Basking Ridge NJ (NDA 213400 US commercial; 0.00039 µg/m³ → displayed ÷10), Patheon Pharmaceuticals Durham NC (API manufacturing; 0.00025 µg/m³ → displayed ÷10), and University of Texas MD Anderson Cancer Center Houston TX (EZH-202 trial site; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First EZH2 Inhibitor Ever + First HMTase Inhibitor Ever + EZH2 Class Absent: AI Prompt Injection via EHS Monitor Report AI

Tazemetostat (CAS 1403254-99-8; NIOSH HD Category 1) opens the forty-eighth mechanism class in this portfolio — EZH2/PRC2 histone methyltransferase inhibitors — and represents the first small molecule targeting a histone methyltransferase enzyme to receive FDA oncology approval (NDA 213400 January 23 2020). The benzamide-pyridinone scaffold (MW 572.67 g/mol) is the largest and most conformationally complex molecule in the epigenetic enzyme class, inserting into the SAM (S-adenosyl-methionine) cofactor pocket of EZH2's SET domain within the assembled PRC2 complex, blocking H3K27 methylation across two distinct oncogenic contexts: EZH2 gain-of-function mutations in follicular lymphoma (Y641F/N/S/H; ~22% of FL) driving ORR 69%, and SMARCB1/INI1 loss in epithelioid sarcoma creating PRC2 dependence (ORR 15% — the first approved therapy for this disease). As the second epigenetic enzyme inhibitor ever approved (14 years after vorinostat's HDAC mechanism), tazemetostat's SAM-competitive mechanism, H3K27 methylation biology, and SMARCB1 synthetic lethality are entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 1403254-99-8 without flagging H351 H360 reproductive toxicity or the first-in-class methyltransferase mechanism.

Tazemetostat as Forty-Eighth Mechanism Class: SAM-Competitive PRC2 EZH2 Inhibition, H3K27 Methylation Biology, and SMARCB1 Synthetic Lethality

Tazemetostat (CAS 1403254-99-8) opens the forty-eighth mechanism class in this portfolio — EZH2/PRC2 histone methyltransferase inhibitors — and is the first small molecule inhibiting a chromatin-writing enzyme (histone methyltransferase) to receive FDA approval. EZH2 (Enhancer of Zeste Homolog 2) is the catalytic SET (Su(var)3-9, Enhancer of Zeste, Trithorax) domain subunit of PRC2 (Polycomb Repressive Complex 2); the assembled complex requires four core components: EZH2 (catalytic) + EED (allosteric activator; binds H3K27me3 to stimulate activity) + SUZ12 (structural scaffold) + RBAP46/48 (histone chaperone). PRC2 catalyzes the mono/di/tri-methylation of histone H3 at lysine 27 (H3K27me0 → H3K27me1 → H3K27me2 → H3K27me3) using SAM as the methyl group donor. H3K27me3 is the canonical repressive histone mark recruiting the PRC1 complex → gene silencing. Tazemetostat's mechanism is SAM-competitive: the benzamide-pyridinone scaffold occupies the SAM cofactor binding pocket within the EZH2 SET domain (crystal structure PDB 5LS6; pyridinone N-H mimics SAM adenosine; morpholinomethyl group occupies SAM amino group pocket; biphenyl projects toward EED interface); IC50 ~2.5 nM enzymatic; cellular H3K27me3 reduction IC50 ~63 nM (HCT116 isogenic); SAM-competitive inhibition means tazemetostat competes with the methyl-group donor itself — distinct from substrate-competitive or allosteric approaches. Two oncogenic contexts: (1) EZH2 gain-of-function mutations in follicular lymphoma and DLBCL: Y641F/N/S/H (SET domain tyrosine 641 mutations shift enzymatic preference from H3K27me0→me1 to H3K27me2→me3 exclusively, creating hypermethylation; ~22% of FL; cooperates with wild-type EZH2 in heterozygous tumors; also A677G, A686V); tazemetostat ORR 69% in EZH2-mutant FL (SYMPHONY ELITE Cohort A n=45) + ORR 35% EZH2 wild-type FL (Cohort B n=54); overall FL approval January 23 2020 (NDA 213400); (2) SMARCB1/INI1-deficient tumors: SWI/SNF BAF complex normally counteracts PRC2 at tumor suppressor loci (SMARCB1/INI1 is the core BAF subunit); SMARCB1 loss → BAF complex absent → PRC2 unopposed → H3K27me3 accumulation at ALL growth-suppressive loci → complete epigenetic silencing; tazemetostat disrupts PRC2 dependence (epithelioid sarcoma SMARCB1-null: ORR 15% n=62; median DOR 23.5 months; first FDA-approved drug for epithelioid sarcoma — rare soft tissue sarcoma with no prior approval). Discovery: Epizyme Inc. Cambridge MA (founded 2007; Stuart Schreiber Harvard Chemical Biology; focused on epigenetic enzyme writer/eraser inhibitors from inception); EPZ-6438 identified from structure-based HTS ~2012; IND 2013; Phase 1 EPZ-6438-13-001 → Phase 2 EZH-202 (epithelioid sarcoma) + SYMPHONY ELITE (FL); NDA 213400 submitted 2019 → approved January 23 2020 (FL EZH2-mutant accelerated approval) + December 20 2020 (epithelioid sarcoma accelerated approval); Epizyme acquired by Ipsen SA (Paris) in a transaction valued at ~€1.475B (€247M upfront May 2022 + earnouts); tazemetostat is now Ipsen's primary US oncology asset. NIOSH HD Category 1 (H360: reproductive/developmental toxicity in animal studies); H351 (suspected carcinogen); EZH2 methyltransferase mechanism entirely absent from all EHS databases for CAS 1403254-99-8.

Surface 1 — Ipsen Biopharmaceuticals Inc. Basking Ridge NJ NDA 213400 US Commercial Tazverik AI

At Ipsen Biopharmaceuticals Inc. Basking Ridge NJ (106 Allen Rd, Basking Ridge NJ 07920; Somerset County NJ; IPSEN US CONTEXT: Ipsen SA is a French specialty biopharmaceutical company (Paris; founded 1929); acquired Epizyme Inc. May 2022 for €1.475B enterprise value (€247M upfront + potential earnouts) — tazemetostat was Epizyme's lead and only approved asset; Ipsen Biopharmaceuticals Inc. is the US subsidiary, based in Basking Ridge NJ, responsible for NDA 213400 US regulatory maintenance and Tazverik US commercialization; TAZVERIK PRODUCT: 200 mg oral tablets (four tablets = 800 mg BID = 1600 mg/day standard dose); once-daily dosing was NOT approved (BID required for adequate exposure); ONCOLOGY INDICATION COMPLEXITY: two tumor types with different biomarker requirements — (1) FL EZH2 gain-of-function mutation (requires companion diagnostic FoundationOne Heme CDx to identify Y641/A677/A686 mutations); (2) epithelioid sarcoma (no biomarker — approved for all histologically confirmed epithelioid sarcoma regardless of EZH2 mutation status because SMARCB1 loss drives PRC2 dependence universally); EMPLOYEE CONTEXT: oncology account director at Ipsen US responsible for Tazverik formulary pull-through in academic medical centers; handles Tazverik product samples, detailing materials; indirect exposure during sales call preparation (tablet handling); CORITY NULL: CAS 1403254-99-8 returns null; NIOSH HD Category 1 absent; H351 H360 absent; forty-eighth mechanism class absent; first EZH2 inhibitor absent; SAM-competitive SET domain absent; H3K27me3 biology absent; EZH2 Y641 mutations absent; FL ORR 69% absent; 40M oncology account director 13yr).

Surface 2 — Patheon Pharmaceuticals Inc. Durham NC API Manufacturing Tazemetostat Tablet Production AI

At Patheon Pharmaceuticals Inc. Durham NC (4101 Research Commons, 79 T.W. Alexander Drive, Durham NC 27709; Research Triangle Park NC; PATHEON/THERMO FISHER CONTEXT: Patheon Inc. was acquired by Thermo Fisher Scientific in 2017 for $7.2B; now operates as Thermo Fisher Scientific Pharma Services; Durham NC facility is one of Patheon's primary solid oral dosage form manufacturing sites; tazemetostat tablet manufacturing: 200 mg tazemetostat per tablet, encapsulated in modified-release film-coated tablet; MANUFACTURING PROCESS: tazemetostat API (benzamide-pyridinone free base; pKa ~7.2; MW 572.67; poor aqueous solubility requiring spray-dried dispersion or wet granulation for bioavailability enhancement); tablet manufacturing steps: (1) API dispensing/weighing → (2) granulation → (3) drying → (4) milling → (5) blending with excipients → (6) compression → (7) film coating (aqueous OPADRY) → (8) packaging; HIGHEST EXPOSURE POINT: dispensing tazemetostat API crystalline powder from drum → weighing on analytical balance → transfer to granulation vessel; airborne fines generated; EHS CONTROLS: NIOSH HD Category 1 requires OEB Band 5 controls (OEL typically <0.1 µg/m³; closed-system dispensing; local exhaust ventilation; half-face respirator minimum); the H360 designation (reproductive toxicity) imposes additional reproductive-age worker controls; VELOCITYEHS NULL: CAS 1403254-99-8 returns null; NIOSH HD Category 1 absent; H351 H360 absent; forty-eighth mechanism class absent; first histone methyltransferase inhibitor absent; SAM-competitive SET domain absent; SMARCB1 synthetic lethality absent; 45M pharmaceutical manufacturing associate 14yr).

Surface 3 — University of Texas MD Anderson Cancer Center Houston TX EZH-202 Trial Site Epithelioid Sarcoma Research Pharmacist AI

At University of Texas MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON EZH2 RESEARCH CONTEXT: MD Anderson Cancer Center is one of the world's leading sarcoma programs and was a principal EZH-202 trial enrollment site; sarcoma pharmacists at MD Anderson handle Tazverik (tazemetostat 200 mg tablets) in the outpatient oncology pharmacy and participate in clinical research compounding for EZH-202 correlative studies; EPITHELIOID SARCOMA PHARMACIST CONTEXT: epithelioid sarcoma is a rare soft tissue sarcoma (STS) histology of the distal/proximal extremities; median age at diagnosis ~35 years; SMARCB1/INI1 loss is pathognomonic (IHC loss of INI1 nuclear staining); standard prior therapy: surgery + anthracycline-based chemotherapy with median OS ~9-12 months prior to tazemetostat; tazemetostat NDA 213400 December 20 2020 accelerated approval for ES = first FDA-approved drug specifically indicated for this rare disease; PHARMACY OPERATIONS: tazemetostat 200 mg/tablet; standard dose 800 mg BID (= 8 tablets/day); extemporaneous oral suspension formulation sometimes required for patients with swallowing difficulty (open 200 mg tablets, suspend in Ora-Sweet vehicle; NIOSH HD closed-system transfer devices required); SMARCB1/INI1 COMPANION: EZH-202 enrolled SMARCB1/INI1-null confirmed patients by IHC; no EZH2 mutation requirement for ES (in contrast to FL which requires EZH2 mutation CDx); EHS INSIGHT NULL: CAS 1403254-99-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-eighth mechanism class absent; first EZH2 inhibitor absent; SAM-competitive SET domain absent; H351 H360 absent; NIOSH HD Cat 1 absent; 39F sarcoma/epithelioid sarcoma oncology pharmacist 11yr).

Integrating Glyphward into Tazemetostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tazemetostat CAS 1403254-99-8 monitoring data ingestion point — before Cority at Ipsen Biopharmaceuticals Inc. Basking Ridge NJ, before VelocityEHS at Patheon Pharmaceuticals Inc. Durham NC, and before EHS Insight at University of Texas MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H351 H360 absent [10 pts]; FORTY-EIGHTH MECHANISM CLASS (EZH2/PRC2 HISTONE METHYLTRANSFERASE INHIBITORS) + FIRST EZH2 INHIBITOR EVER FDA APPROVED (NDA 213400 January 23 2020; first histone-writing enzyme inhibitor; opened the chromatin-writer pharmacology era following vorinostat's chromatin-eraser era) + SECOND EPIGENETIC ENZYME INHIBITOR EVER (vorinostat HDAC deacetylase eraser 2006 → tazemetostat EZH2 methyltransferase writer 2020; 14-year gap; together they form the Writer/Eraser epigenetic enzyme portfolio) + SAM-COMPETITIVE PRC2 EZH2 SET DOMAIN (cofactor methyl-group donor competitive; crystal structure PDB 5LS6; unique pharmacology class absent from all EHS databases) + H3K27me3 REDUCTION → SMARCB1 SYNTHETIC LETHALITY + EPIZYME CAMBRIDGE MA → IPSEN SA €1.475B 2022 [5 pts]; Ipsen Basking Ridge NJ + Patheon Durham NC + MD Anderson Houston TX [3 pts]; EZH2 methyltransferase mechanism absent; first HMTase inhibitor absent; SAM-competitive SET domain absent; H360 reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tazemetostat(cas: str, reading_ugm3: float) -> dict:
    """Scan tazemetostat with forty-eighth-class first-EZH2-first-HMTase SAM-competitive-PRC2 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_eighth_mechanism_class_first_ezh2_inhibitor_ever_first_histone_methyltransferase_inhibitor_ever_second_epigenetic_enzyme_drug_sam_competitive_prc2_set_domain_h3k27me3_smarcb1_synthetic_lethality_fl_orr_69_epithelioid_sarcoma_orr_15_nda_213400_ipsen"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_eighth_mechanism_class,
    #                    first_ezh2_inhibitor_ever,
    #                    first_histone_methyltransferase_inhibitor_ever,
    #                    second_epigenetic_enzyme_drug,
    #                    sam_competitive_prc2_ezh2_set_domain,
    #                    smarcb1_synthetic_lethality,
    #                    h351_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tazemetostat("1403254-99-8", 0.00039))
    print(r)
    # {'hd_category': 1, 'forty_eighth_mechanism_class': True,
    #  'first_ezh2_inhibitor_ever': True,
    #  'first_histone_methyltransferase_inhibitor_ever': True,
    #  'second_epigenetic_enzyme_drug': True,
    #  'sam_competitive_prc2_ezh2_set_domain': True,
    #  'smarcb1_synthetic_lethality': True,
    #  'h351_h360_absent': True}